SWP
ALNY icon

Stratos Wealth Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Stratos Wealth Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-200
Closed -$18K – 913
2018
Q3 		$18K Buy
+200
New +$20.1K ﹤0.01% 1919
2018
Q2 		– Sell
-200
Closed -$24K – 1022
2018
Q1 		$24K Hold
200
– – ﹤0.01% 1943
2017
Q4 		$25K Buy
+200
New +$25.1K ﹤0.01% 1825

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Stratos Wealth Partners's ALNY Position: Q4 2018 in Review

Stratos Wealth Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2018, closing a stake of 200 shares — an estimated $18K sold.

Stratos Wealth Partners first reported a position in ALNY in Q4 2017 and held it in 3 quarters. The position peaked at $25K in Q4 2017. 284 funds tracked by Wall St. Rank hold ALNY as of Q4 2018.

  • Stratos Wealth Partners reported no remaining Alnylam Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 200 Alnylam Pharmaceuticals shares in Q4 2018, an estimated $18K.
  • Stratos Wealth Partners first reported a position in Alnylam Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Stratos Wealth Partners's Alnylam Pharmaceuticals position peaked at $25K in Q4 2017.
  • 284 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2018.

Based on Stratos Wealth Partners's 13F filing for Q4 2018, filed 8 Feb 2019.